A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Summary

This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.

Timeline

Start

2005-11

Primary completion

2007-05

Completion

2007-05

Drugs

Indications